Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:59:16 2024-06-25 EDT			5-day change	1st Jan Change
0.6202 ^USD	-7.29%		-7.56%	-52.29%

05-15	Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-14	Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	MT

ENVERIC BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 15, 2021 at 04:18 pm

Item 8.01 Other Events.

On January 15, 2021, Enveric Biosciences, Inc. issued a press release announcing the closing of the previously announced registered direct offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
  No.     Description

99.1        Press Release, dated January 15, 2021

Latest news about Enveric Biosciences, Inc.

Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	05-14	MT
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	05-14	CI
Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	05-08	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Sector Update: Health Care Stocks Rise Late Afternoon	03-19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19	MT
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	03-19	MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	03-19	MT
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	03-19	CI
Enveric Biosciences Issues 228,690 Shares in Direct Offering	03-11	MT
Top Midday Gainers	02-29	MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	02-29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	02-29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	02-23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	02-23	MT
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	02-23	MT
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	02-21	CI
HC Wainwright Initiates Enveric Biosciences With Buy Rating, Price Target is $10	01-30	MT
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	01-03	CI
Enveric Bioscience Generates $1.8 Million as Investors Exercise Warrants	12-29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	12-28	MT
Health Care Up on Defensive Bias -- Health Care Roundup	12-28	DJ
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	12-28	CI
Enveric Biosciences Selects EB-003 as Lead Drug Candidate to Treat Mental Health Disorders	12-28	MT

Chart Enveric Biosciences, Inc.

Duration

Period

More charts

Company Profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Sector

Biotechnology & Medical Research

Calendar

2025-03-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6202 USD

Average target price

9 USD

Spread / Average Target

+1,351.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENVERIC BIOSCIENCES, INC.	-52.29%	4.81M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+36.73%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research